Evidence map›Paper›PMID 42747956›Full record

ArticleSTAR protocols2026

Protocol for robust gene knockout and reliable validation in human cell lines using quad-guide RNA vectors.

Michael Tobin, Jie Dai, Li-Chuan Chan, Weiwei Guo

Abstract read
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael TobinOncology Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Jie DaiOncology Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Li-Chuan ChanOncology Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. Electronic address: li-chuan.chan@boehringer-ingelheim.com.
Weiwei GuoOncology Department, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. Electronic address: weiwei_2.guo@boehringer-ingelheim.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas9 is a powerful tool for editing genomic loci, however achieving high knockout efficiency at certain targets remains challenging. Here, we present a protocol for gene knockout using an all-in-one, quad-guide RNA-expressing vector. We describe steps for plasmid construction, virus preparation, transduction, and subsequent gene editing and functional validation within DLD-1 colorectal adenocarcinoma cells. This strategy provides an efficient workflow for gene knockout that is rapidly confirmed through PCR amplification of mRNA derived from the targeted gene loci.

Indexed as

Biotechnology and bioengineeringCRISPRGenetics

Identifiers

PMID42747956
PMCPMC13597292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.